The deal with a company owned by Embraer gives Beta Technologies an additional source of revenue as it develops its own electric aircraft. By Niraj Chokshi Two companies racing to develop electric ...

A process developed at ETH Zurich enables the massive miniaturisation of organic light-emitting diodes (OLEDs) in only one single step. The light sources are now smaller than the wavelength of the ...

Nov 4 (Reuters) - Electric aircraft maker Beta Technologies (BETA.N), opens new tab was valued at $7.44 billion after its shares opened flat in their New York Stock Exchange debut on Tuesday, ...

In a change of pace, one company operating in the aerospace sector is expected to make its market debut today. Here’s what you need to know about Beta Technologies and its initial public offering: ...

Read Seven Days’ November 5, 2025, cover story on Beta here. Vermont electric aviation startup Beta Technologies raked in more than $1 billion on Tuesday as it debuted on the New York Stock Exchange ...

BETA Technologies is following a vertically integrated model similar to Tesla’s, starting with niche markets (cargo, defense) before expanding into passenger aviation. BETA's robust order backlog, ...

BETA Technologies is seeking at least $100 million in a US IPO to fund its electric aircraft development and commercialization. The firm is in mid-to-late-stage FAA certification for various aircraft, ...

Beta Technologies has a partnership with GE Aerospace IPO market reopens for high-growth startups Beta's aircraft used by US military and FAA Sept 29 (Reuters) - Electric aircraft maker Beta ...

Apple has just released the first public betas for iOS 26.1 and more. Here’s what’s new in iOS 26.1 public beta 1. New features and changes in iOS 26.1 beta 1 iOS 26.1 is the next big update coming ...

Two new studies point in opposite directions. A large new study conducted in Spain and Italy found that beta blockers, drugs often used to slow the heart rate and lower blood pressure, did not provide ...

A class of drugs called beta-blockers — used for decades as a first-line treatment after a heart attack— doesn’t benefit the vast majority of patients and may contribute to a higher risk of ...